ODY-CDK

ODY-CDK is a potent, selective, and brain-penetrant small molecule inhibitor of cyclin-dependent kinase 2 (CDK2), developed by Odyssey Therapeutics. It is designed to treat cancers characterized by CCNE1 amplification or RB1 loss-of-function mutations, particularly those with brain metastases or at high risk of developing them, such as triple-negative breast cancer (TNBC), small cell lung cancer (SCLC), and non-small cell lung cancer (NSCLC). ODY-CDK demonstrates high selectivity (40 to 180-fold) over other CDK family members (CDK1, 5, 6, 7, and 9) and has shown significant intracranial antitumor activity in preclinical models, outperforming non-brain-penetrant clinical-stage CDK2 inhibitors like PF-07104091.